How it works
LGD4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. Ligandrol has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers. This randomized, double-blind, placebo-controlled Phase I study established the safety and tolerability up to doses of 22 mg per day.
LGD4033 underwent several recent studies and trials to find the best and safest way to use it. From these trials, the results have shown increases in lean body mass and decreases in body fat. Ligandrol shows a significant increase in strength, well being, as well as healing from injuries.
LGD has shown the most ability of any SARM to put on size that could be considered a bulk. This will, of course, be dependent upon the diet used. Users that have experienced more than 10lb. increases, and have had a significant increase in calorie intake. The possibility of this type of size is present with LGD4033 use. A recommend dosage for this type of goal would be 5-10 mg day for 8 weeks.
In addition, Ligandrol shines with recomposition. Many have seen an increase in lean body mass and a decrease in body fat. LGD4033 seems to work the best with this method. Ran in conjunction with other SARMS, like Cardarine (GW501516), will only increase the likelihood of a stronger recomp. Recommended doses for recomping would be 5-8 mg a day for 8 weeks.
Ligandrol can be used to cut as well. It will shine more-so if ran in conjunction with SARMS S-4 and Cardarine (GW-501516). This would be similar to a SARMS triple stack that is normally ran with Ostarine, except there is a possibility of more size being put on while cutting. A good dose for this method would be 3-5 mg a day for 8 weeks.
Through studies and logs, the side effects from LGD4033 have so far shown to be minimal. The suppression shown has been dose dependent, but there has been a decrease in total and free testosterone as well as SHBG. These interesting findings have show NO significant decrease in LH or FSH. This is very encouraging to users as it shows that while suppressive, recovery will still not be near as long as with anabolic steroids. LGD is non toxic and side effects have been mild to minimal. It has not shown increases in estradiol ,but, as with anything, an aromatase inhibitor should be kept on hand.
Read more about LGD4033
The safety, pharmacokinetics, and effects of LGD–4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.